EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Evaluation of the efficacy of a live attenuated vaccine (porcimune PRRS MLV) against porcine reproductive and respiratory syndrome virus in landrace piglets

Carlos A García-Munguía, María R Robles-López, Dhamar A Ramírez-Castillo, Raúl R Robles-de la Torre, Gloria P Galaviz-Martínez, José N Aguilar-Toribio, Alejandro Flores-Montenegro, Pablo Pineyro, Fabián Correa-Morales, Otilio García-Munguía, Miguel Ángel Plascencia-Espinosa, Alberto M García-Munguía

Translational Animal Science · 2026-01-15 · 10

DOI: 10.1093/tas/txag176 ↗
AbstractBibliografische Angaben

Abstract

Abstract Porcine reproductive and respiratory syndrome virus (PRRSV) represents a constant challenge for the swine industry, both in Mexico and internationally, due to its high genetic variability and immunosuppressive capacity. This study evaluated the comparative efficacy of four modified-live vaccines in 3 to 4-wk-old seronegative piglets challenged intramuscularly with the heterologous PRRSV strain DAP150520 at 35 d post-vaccination (dpv; 0 d post-challenge, dpc). Fifty piglets were randomly allocated into five groups (n = 10/group): G1, ATCC-VR-2332; G2, SJO151012 ≥ 104 (Porcimune); G3, P129; G4, attenuated Nebraska ≥ 4.0; and G5, unvaccinated controls. Outcomes included ELISA seroconversion, qRT-PCR cycle threshold (Ct) values (PRRSV RNA detection), daily clinical scoring, BW, and gross lung lesions assessed using the modified Madec scale at 7 dpc. Group 2 (Porcimune) showed complete seroconversion from 21 dpv, controlled post-challenge viremia (cycle threshold [Ct] = 21.84 at 7 dpc), and a 57% reduction in lung lesions compared with controls. Group 1 (ATCC-VR-2332) also reached complete seroconversion by 21 dpv, whereas Group 3 (P129) showed early but fluctuating seroconversion and Group 4 (attenuated Nebraska) showed delayed and inconsistent seroconversion across sampling points, and Group 5 (control) remained seronegative until after challenge. Group 3 achieved a 63% reduction in lung damage, although with a more variable immune response. In contrast, G1, G4, and the control group showed lung lesions in 100% of animals after challenge. Post-challenge BW gain was significantly greater in G1 and G2 than in the unvaccinated control (one-way ANOVA, P = 0.023; Tukey’s HSD, P = 0.039 and P = 0.045, respectively), meanwhile the control group showed a net BW loss after challenge. Overall, under these experimental conditions, Porcimune PRRS MLV was the only vaccine that differed significantly from unvaccinated controls in lung lesions, post-challenge BW gain and ELISA S/P ratio, supporting its protective potential against a heterologous PRRSV challenge.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →